MDRAAC

The feature of our product antibody- antibiotic conjugate drugs is that two different drugs can be bonded to the antibody to provide a feasible strategy for bacterial resistance. Our product mainly targets patients with recurrent infection caused by Klebsiella pneumoniae, and combines the antibiotics and antibody-antibiotic conjugated drugs development.